Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data.
Bottom Line: In cohort 2, overall, there were contrasting findings between patients in the GLA-S and those in the DET-C subgroup.This study showed contrasting results when patients with T2DM switched between basal insulin analogues, although these preliminary results may be subject to limitations in the analysis.Nevertheless, this study calls into question the therapeutic interchangeability of GLA and DET, and this merits further investigation.
Affiliation: Model Clinical Research, Baltimore, MD, USA.Show MeSH
Related in: MedlinePlus
Mentions: A total of 25 290 eligible patients were identified with 19 811 patients from cohort 1 (GLA-C, n = 17 783 and DET-S, n = 2028) and 5479 from cohort 2 (DET-C, n = 4431 and GLA-S, n = 1048). Patient attrition is shown in Figure 1. Significant baseline differences existed between the subgroups in each cohort (Table S1). In cohort 1, when compared with patients in the DET-S subgroup, patients in the GLA-C subgroup were older, were more likely to be black, were more likely to reside in the Midwest or West, were more likely to be enrolled in Medicare, had higher CCI scores and had lower HbA1c values. No significant differences were found for BMI or body weight between the GLA-C and DET-S subgroups at baseline. In cohort 2, when compared with the DET-C subgroup, patients in the GLA-S subgroup were younger, were more likely to be black, were more likely to reside in the Midwest or West, had higher HbA1c values, and had higher body weight and BMI values. Patients in the GLA-S and DET-C subgroups had similar CCI scores at baseline. For both cohorts, no significant differences were found for baseline hypoglycaemic events between groups.